Breast cancer

Koning Announces First New York Metropolitan Area Installation of Revolutionary Koning Vera Breast CT at Community Radiology NY

Retrieved on: 
Mercredi, avril 17, 2024
Compression, Society, Radiology, Mammography, Woman, Health, Breast, Incidence, Patient, KBCT, Neoplasm, Diagnosis, Canal Street, Breast cancer, Medical imaging

NEW YORK, April 17, 2024 /PRNewswire/ -– Koning Health , a leader in innovative medical imaging technology, is proud to announce the first installation of its groundbreaking Koning Vera Breast CT system in the New York City metropolitan area at Community Radiology NY on Canal Street.

Key Points: 
  • NEW YORK, April 17, 2024 /PRNewswire/ -– Koning Health , a leader in innovative medical imaging technology, is proud to announce the first installation of its groundbreaking Koning Vera Breast CT system in the New York City metropolitan area at Community Radiology NY on Canal Street.
  • The excitement of this installation comes on the tail end of a successful showcasing of Koning's Breast CT device at the Society of Breast Imaging Symposium in Montreal.
  • "We are thrilled to bring the Koning Vera Breast CT to Community Radiology.
  • "The addition of the Koning Vera Breast CT to our diagnostic tools allows us to provide our patients with the latest in medical imaging.

Dahua Technology Releases 2023 ESG Report

Retrieved on: 
Mercredi, avril 17, 2024
Social, Ecosystem, Artificial intelligence of things, WEEE, Biodiversity, Certification, Electricity, ISO, Carbon, Environment, Dahua Technology, Dahua, Privacy, ESG, Welfare, ISO 27001, ISO14001, Ethics, United Nations Global Compact, Breast cancer, Hazardous waste, Renewable energy

HANGZHOU, China, April 17, 2024 /PRNewswire/ -- Dahua Technology, a world-leading video-centric AIoT solution and service provider, has unveiled its 2023 Environmental, Social and Governance Report, highlighting diverse range of initiatives aimed at addressing pressing environmental and social challenges while enhancing responsible corporate practices.

Key Points: 
  • HANGZHOU, China, April 17, 2024 /PRNewswire/ -- Dahua Technology, a world-leading video-centric AIoT solution and service provider, has unveiled its 2023 Environmental, Social and Governance Report, highlighting diverse range of initiatives aimed at addressing pressing environmental and social challenges while enhancing responsible corporate practices.
  • Dahua boasts a transparent, well-established ESG governance framework, adhering to compliance operations and business ethics.
  • At the forefront of technological innovation, Dahua adopts clean technology and advanced simulation processes for green product research and development to minimize the impact on the environment.
  • Dahua also incorporates ESG standards into supplier screening and evaluation to promote the sustainable development of its supply chain.

Dahua Technology Releases 2023 ESG Report

Retrieved on: 
Mercredi, avril 17, 2024
Social, Ecosystem, Artificial intelligence of things, WEEE, Biodiversity, Certification, Electricity, ISO, Carbon, Environment, Dahua Technology, Dahua, Privacy, ESG, Welfare, Multimedia, ISO 27001, ISO14001, Ethics, United Nations Global Compact, Breast cancer, Hazardous waste, Renewable energy

HANGZHOU, China, April 17, 2024 /PRNewswire/ -- Dahua Technology, a world-leading video-centric AIoT solution and service provider, has unveiled its 2023 Environmental, Social and Governance Report, highlighting diverse range of initiatives aimed at addressing pressing environmental and social challenges while enhancing responsible corporate practices.

Key Points: 
  • HANGZHOU, China, April 17, 2024 /PRNewswire/ -- Dahua Technology, a world-leading video-centric AIoT solution and service provider, has unveiled its 2023 Environmental, Social and Governance Report, highlighting diverse range of initiatives aimed at addressing pressing environmental and social challenges while enhancing responsible corporate practices.
  • Dahua boasts a transparent, well-established ESG governance framework, adhering to compliance operations and business ethics.
  • At the forefront of technological innovation, Dahua adopts clean technology and advanced simulation processes for green product research and development to minimize the impact on the environment.
  • Dahua also incorporates ESG standards into supplier screening and evaluation to promote the sustainable development of its supply chain.

RSNA and GE HealthCare Bring Advanced Mammography Technology to Tanzania to Improve Access and Help Address Breast Cancer Mortality Rate

Retrieved on: 
Mardi, avril 16, 2024
Education, Mortality, MUHAS, Cancer, Radiology, Learning, Mammography, GE HealthCare, NNSA, Woman, Certification, Breast cancer, Curriculum, GLC, Nursing, CEM, RSNA, Physician, National Nuclear Security Administration, Diagnosis, Health, 2D, Imaging, Organization, Muhimbili National Hospital, MNH, Medical imaging

The project aims to help lower Tanzania's 50% breast cancer mortality rate through early detection and efforts to expand clinical education.

Key Points: 
  • The project aims to help lower Tanzania's 50% breast cancer mortality rate through early detection and efforts to expand clinical education.
  • [2] Additionally, the lifetime risk for developing breast cancer is approximately one in twenty, and approximately half of all women diagnosed with breast cancer in the country die of the disease.
  • "With breast cancer mortality rates in Tanzania among the highest globally, our work with RSNA will help bring much-needed mammography technology to MUHAS.
  • GE HealthCare and RSNA will join the team at Muhimbili National Hospital to celebrate this collaboration on Wednesday, April 17, 2024 at the breast center's unveiling.

Karmanos Brings Successful Cancer Screening and Prevention Event to Farmington Hills

Retrieved on: 
Lundi, avril 15, 2024
Cancer, COVID, Save, Woman, Health, Diabetes, Breast, Insurance, Female, Patient, Karmanos Cancer Institute, Education, Cholesterol, Movement, HPV, ID, Breast cancer, Meditation

DETROIT, April 15, 2024 /PRNewswire/ -- The Barbara Ann Karmanos Cancer Institute invites the community to the Screening Saves Lives: Cancer Screening and Educational Event in Farmington Hills. It takes place on Saturday, June 8, 2024, from 9 a.m. – 2 p.m. at the Lawrence and Idell Weisberg Cancer Center at 31995 Northwestern Highway. Karmanos will provide breast cancer screenings, including mammograms, colorectal screening consultations, free head and neck examinations, and wellness checks.

Key Points: 
  • DETROIT, April 15, 2024 /PRNewswire/ -- The Barbara Ann Karmanos Cancer Institute invites the community to the Screening Saves Lives: Cancer Screening and Educational Event in Farmington Hills.
  • Karmanos will provide breast cancer screenings, including mammograms, colorectal screening consultations, free head and neck examinations, and wellness checks.
  • Plus, Karmanos will provide information about their Screening and Prevention Program , the Karmanos Genetic Counseling Service , the Women's Wellness Clinic , and clinical trials .
  • Screening Saves Lives: Cancer Screening and Educational Event is open to the public.

IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate: Data Submitted to FDA Requesting Marketing Authorization to Treat Early-Stage Breast Cancer

Retrieved on: 
Lundi, avril 15, 2024
Luminal, Cryoablation, FDA, CMS, Kidney, Meta-analysis, LUMINA, Risk, Woman, Food, Economics, Freezing, Marketing, Recurrence, Breast, PRISMA, Patient, Liver, LN2, CPT, Society, Classification, Physician, Medicare, Neoplasm, Patient satisfaction, Clinical trial, Annual general meeting, ICE3, Breast cancer, Birth control

The ICE3 study was the largest controlled multicenter clinical trial ever performed for liquid nitrogen (LN2) based cryoablation of low-risk, early-stage malignant breast tumors.

Key Points: 
  • The ICE3 study was the largest controlled multicenter clinical trial ever performed for liquid nitrogen (LN2) based cryoablation of low-risk, early-stage malignant breast tumors.
  • ICE3 results are also in line with data from real-world use of ProSense® by third parties in territories where IceCure's cryoablation system is used to treat early-stage breast cancer.
  • Driven by favorable healthcare economics combined with patient satisfaction and demand, we expect rapid adoption pending FDA granting the DeNovo Classification Request for Marketing Approval."
  • Dr. Fine gave an oral presentation titled "Cryoablation Without Excision for Early-Stage Breast Cancer; ICE3 Trial 5 year follow up on Ipsilateral Breast Tumor Recurrence."

U.S. Environmental Protection Agency Targets 'Cancer Alleys'

Retrieved on: 
Vendredi, avril 12, 2024
Public, Cancer, LLP, EPA, Risk, Vinyl chloride, CNN, Environment, Cancer Alley, Chloroprene, Empathy, Ethylene oxide, Organization, Breast cancer, Benzene, Air pollution, Environmental remediation

NOVATO, Calif., April 12, 2024 /PRNewswire-PRWeb/ -- On Tuesday, April 9, 2024, Brayton Purcell, LLP learned that in a critical development for community health, the US Environmental Protection Agency (EPA) introduced comprehensive regulations aimed at curbing industrial pollution. This significant measure targets a range of dangerous pollutants, including ethylene oxide, chloroprene, benzene, vinyl chloride, 1,3-butadiene, and ethylene dichloride. This move represents a key step in the EPA's ongoing effort to reduce environmental contamination and the associated health risks.

Key Points: 
  • The US Environmental Protection Agency (EPA) introduced comprehensive regulations aimed at curbing industrial pollution.
  • NOVATO, Calif., April 12, 2024 /PRNewswire-PRWeb/ -- On Tuesday, April 9, 2024, Brayton Purcell, LLP learned that in a critical development for community health, the US Environmental Protection Agency (EPA) introduced comprehensive regulations aimed at curbing industrial pollution.
  • This move represents a key step in the EPA's ongoing effort to reduce environmental contamination and the associated health risks.
  • The US Environmental Protection Agency (EPA) introduced comprehensive regulations aimed at curbing industrial pollution.

Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance

Retrieved on: 
Jeudi, avril 11, 2024
Breast cancer, VUS, Medical school, Patient, Oncogenomics, Laboratory, OTC, FACMG, Machine learning, Research, Health, REA, Genetic testing, Black, DSM-IV codes, Classification, Society, Cancer, Algorithm, SAN, Gene

SAN FRANCISCO, April 11, 2024 /PRNewswire/ -- Invitae (OTC: NVTA), a leading medical genetics company, today announced new studies to be presented at the American Society of Breast Surgeons Annual Meeting (ASBrS) held in Orlando from April 10-14, 2024. The featured research will highlight how machine learning can reduce variants of uncertain significance (VUS) in patients who have received genetic testing for breast cancer, in addition to results from real world data showing that uncertain results do not lead to an overuse of mastectomies for breast cancer patients.

Key Points: 
  • The featured research will highlight how machine learning can reduce variants of uncertain significance (VUS) in patients who have received genetic testing for breast cancer, in addition to results from real world data showing that uncertain results do not lead to an overuse of mastectomies for breast cancer patients.
  • After validating gene-specific machine learning algorithms, the impact on variant classification was analyzed in patients with breast cancer who underwent hereditary cancer genetic testing from January 2022 - May 2023.
  • Results offer reassurance that variants of uncertain significance in genetic testing results among breast cancer patients do not lead to overuse of breast surgeries, like mastectomies.
  • This study titled, "Real-World Breast Surgery Utilization among Breast Cancer Patients with Germline Variants of Uncertain Significance," examines breast surgery uptake in a large, recent sample of breast cancer patients undergoing genetic testing.

ImpediMed to Present Chronic Breast Cancer-related Lymphedema Study Results at American Society of Breast Surgeons Annual Meeting

Retrieved on: 
Jeudi, avril 11, 2024
FDA, Cancer, American Cancer Society, Risk, Woman, Cleveland Clinic, Lymphedema, Research, Body composition, BIS, Patient, Society, Melanoma, MBA, Quality of life, Breast cancer, Medical imaging

CARLSBAD, Calif., April 11, 2024 /PRNewswire/ -- ImpediMed, a leader in medical technologies to clinically monitor and manage fluid and body composition, announced today that it will present new results from a breast cancer-related lymphedema study during a poster session at the American Society of Breast Surgeons (ASBrS) Annual Meeting in Orlando, FL on Friday, April 12, 2024.

Key Points: 
  • CARLSBAD, Calif., April 11, 2024 /PRNewswire/ -- ImpediMed , a leader in medical technologies to clinically monitor and manage fluid and body composition, announced today that it will present new results from a breast cancer-related lymphedema study during a poster session at the American Society of Breast Surgeons (ASBrS) Annual Meeting in Orlando, FL on Friday, April 12, 2024.
  • "Chronic breast cancer-related lymphedema can represent a risk to patients who have undergone breast cancer treatment with meaningful impact on their quality of life," said Chirag Shah, MD, Co-Director of the Comprehensive Breast Cancer Program, Cleveland Clinic, lead author of the study, and scientific adviser to ImpediMed.
  • ImpediMed Chief Medical Officer, Steven L. Chen, MD, MBA, one of the study's authors, will present the findings at ASBrS.
  • According to the American Cancer Society 58% of cancer patients diagnosed with breast cancer, melanoma, or pelvic area cancers are at risk for developing limb lymphedema, and over 80% of breast cancer patients are at risk.

Biotech Innovations Paving the Way in Breast Cancer Fight

Retrieved on: 
Jeudi, avril 11, 2024
AstraZeneca, Breast cancer, Gilead Sciences, FDA, Radiation, University, PARP1, Cancer, Bone marrow, G1 Therapeutics, Paclitaxel, Protein, GILD, Safety, PARP, Pancreatic cancer, News, Progression-free survival, Survival, Estate (law), American Cancer Society, TSX, OS, Fast track (FDA), MBC, ONC, PETRA, Data monitoring committee, Rated R, Patient, Sacituzumab govitecan, Hologic, HOLX, Neoplasm, Death, DMC, AACR, Immune system, Type, TNBC, Trilaciclib, Pharmaceutical industry

VANCOUVER, BC, April 11, 2024 /PRNewswire/ -- USA News Group – The American Cancer Society is projecting 2024 to be the first year ever for the US to have more than 2 million new cases, which would represent a record high. Among 10 of the most common cancers, 6 have seen a rise in diagnoses, including the most common type of cancer in women—breast cancer. According to the World Health Organization breast cancer caused 670,000 deaths globally in 2022, and is predicting a 77% increase in new cancer cases by 2050. Based on the characteristics of each patient's tumor, how each patient is treated may be completely different from others. Broadening our ability to tackle breast cancer are several biotech developments including from Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Gilead Sciences, Inc. (NASDAQ:GILD), G1 Therapeutics, Inc. (NASDAQ:GTHX), AstraZeneca PLC (NASDAQ:AZN), and Hologic, Inc. (NASDAQ:HOLX).

Key Points: 
  • According to the World Health Organization breast cancer caused 670,000 deaths globally in 2022 , and is predicting a 77% increase in new cancer cases by 2050 .
  • Broadening our ability to tackle breast cancer are several biotech developments including from Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Gilead Sciences, Inc. (NASDAQ:GILD), G1 Therapeutics, Inc. (NASDAQ:GTHX), AstraZeneca PLC (NASDAQ:AZN), and Hologic, Inc. (NASDAQ:HOLX).
  • Coming off of a late-2022 FDA Fast Track Designation of Oncolytics Biotech Inc.'s (NASDAQ:ONCY) (TSX:ONC) flagship asset pelareorep for the treatment of pancreatic cancer, momentum is building towards another important FDA milestone, this time for breast cancer.
  • "We are optimistic that pelareorep, in combination with paclitaxel, could significantly enhance clinical outcomes for patients with HR+/HER2- metastatic breast cancer.